Inhibition of Human Immunodeficiency Virus Type 1 Entry by a Keggin Polyoxometalate

Viruses
Xiaoli WangYi Zeng

Abstract

Here, we report the anti-human immunodeficiency virus (HIV) potency and underlying mechanisms of a Keggin polyoxometalate (PT-1, K₆HPTi₂W10O40). Our findings showed that PT-1 exhibited highly potent effects against a diverse group of HIV type 1 (HIV-1) strains and displayed low cytotoxicity and genotoxicity. The time-addition assay revealed that PT-1 acted at an early stage of infection, and these findings were supported by the observation that PT-1 had more potency against Env-pseudotyped virus than vesicular stomatitis virus glycoprotein (VSVG) pseudotyped virus. Surface plasmon resonance binding assays and flow cytometry analysis showed that PT-1 blocked the gp120 binding site in the CD4 receptor. Moreover, PT-1 bound directly to gp41 NHR (N36 peptide), thereby interrupting the core bundle formation of gp41. In conclusion, our data suggested that PT-1 may be developed as a new anti-HIV-1 agent through its effects on entry inhibition.

References

Jun 1, 1991·Chemical & Pharmaceutical Bulletin·Y InouyeS Nakamura
Jan 1, 1990·Chemical & Pharmaceutical Bulletin·Y InouyeS Nakamura
Jan 1, 1989·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·J P AymardF Streiff
Sep 1, 1988·Antimicrobial Agents and Chemotherapy·B L Moskovitz
Dec 13, 2000·Mutation Research·G Krishna, M Hayashi
May 6, 2006·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Katsuaki Dan, Toshihiro Yamase
Jun 2, 2006·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Shiro ShigetaNaoki Yamamoto
Apr 30, 2008·Proceedings of the National Academy of Sciences of the United States of America·Julie A ReadingerPamela L Schwartzberg
Sep 8, 2009·Nature Chemical Biology·Françoise BaleuxHugues Lortat-Jacob
Jan 25, 2011·Bioorganic & Medicinal Chemistry Letters·Andreas FlütschGreta R Patzke
Jun 4, 2011·Nature Protocols·Dirk DaelemansChristophe Pannecouque
Jan 8, 2013·Current Opinion in Virology·Timothy J Henrich, Daniel R Kuritzkes
Jan 22, 2013·Current Drug Metabolism·Kerstin Andrae-MarobelaRunner R T Majinda
Apr 2, 2013·Antiviral Research·Aiman A Haqqani, John C Tilton
Aug 13, 2013·Current Medicinal Chemistry·María José Gómara, Isabel Haro
Aug 28, 2013·The Journal of Clinical Investigation·S Alireza RabiRobert F Siliciano
Sep 13, 2013·Antiviral Research·Yue QiJin Zhong
Feb 15, 2014·Current Opinion in Virology·Gregory B Melikyan
Jun 1, 2014·ACS Applied Materials & Interfaces·Juan WangZhenhui Kang
Nov 28, 2014·Expert Opinion on Therapeutic Patents·Dongmei ZhangShibo Jiang
Dec 3, 2014·Virology·Melissa Zarr, Robert Siliciano
Feb 14, 2015·Antiviral Research·Weizao ChenDimiter S Dimitrov
Jul 15, 2015·Proceedings of the National Academy of Sciences of the United States of America·Alonso HerediaRobert R Redfield
Nov 7, 2015·Trends in Microbiology·Oliver F BrandenbergAlexandra Trkola
Dec 27, 2015·Bioorganic & Medicinal Chemistry Letters·Takaaki MizuguchiHirokazu Tamamura
Jul 28, 2016·BMC Infectious Diseases·Kathryn J BelloJason F Okulicz
Jan 12, 2017·Expert Opinion on Therapeutic Patents·Wen LiShibo Jiang
Apr 23, 2017·Bioorganic & Medicinal Chemistry Letters·Shunyi WangYi Zeng

❮ Previous
Next ❯

Citations

Jul 6, 2018·The Journal of Physical Chemistry. B·Thomas J PaulRajeev Prabhakar

❮ Previous
Next ❯

Methods Mentioned

BETA
enzyme-linked immunosorbent assay
ELISA
flow cytometry
FACS
electrophoresis
Surface
chip
chips
fluorescence resonance

Software Mentioned

BIAvaluation
GraphPad
Enspire
GraphPad Prism

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.